Johnson & Johnson Introduces CERENOVUS – New Neurovascular Business

Johnson & Johnson Medical Devices Companies has introduced its new neurovascular business at the European Society of Minimally Invasive Neurological Therapy (ESMINT) 9th Annual Meeting. The name CERENOVUS is derived from the Latin word that means “new” and “brain”. This neurovascular business is focused on delivering innovative therapies for patients suffering from diseases such as hemorrhagic and ischemic stroke.

In Europe, stroke is one of the growing health concerns and the number of cases is rising annually from 1.1 million in 2000 to 1.5 million by 2025. The American Heart Association estimates that people die of stroke every 4 minutes and the annual cost of stroke is estimated to be 27 Euro Dollar across Europe. This estimated economic cost includes direct cost such as health care services and medication during the treatment and indirect cost like lost productivity.

Gabriele Fischetto, vice president of Johnson & Johnson cardiovascular specialty Solutions in EMEA said, “We believe stroke should not be a life sentence. CERENOVUS is inspired by our long heritage and dedication to improving patient lives. We believe there is no other healthcare company better positioned than us to assist in addressing the real pain points for doctors who treat stroke – from helping them work more efficiently; to achieving a higher success rate across all neurovascular cases.”

Johnson & Johnson Medical Device Companies are committed to neurovascular care thus expanded the CERENOVUS product portfolio in the last year. Cerenovus primarily have the ability to address the unmet clinical needs in the areas of endovascular treatment of wide neck platform.

LEAVE A REPLY

Please enter your comment!
Please enter your name here

19 − 10 =